Literature DB >> 22311264

Jun activation domain-binding protein 1 expression in oral squamous cell carcinomas inversely correlates with the cell cycle inhibitor p27.

Ling Gao1, Shuo Huang, Wenhao Ren, Lu Zhao, Jingwei Li, Keqian Zhi, Yincheng Zhang, Hong Qi, Chen Huang.   

Abstract

The Jun activation domain-binding protein 1 (Jab1) may be involved in degradation of the cyclin-dependent kinase inhibitor p27, but it has not been clarified. In this study, we observed expression levels of Jab1 and p27 in oral squamous cell carcinoma (OSCC) and normal oral mucosa tissue and evaluated whether the Jab1 expression is correlated with p27 protein levels and how it is clinically relevant OSCC. The clinicopathological features and immunohistochemical expression levels of Jab1 and p27 proteins were immunohistochemically studied in 206 specimens from patients who underwent surgical resection for OSCC. Survival analyses were performed by using the Kaplan-Meier method. Jab1 overexpression was detected in 83% (171 of 206) of OSCCs and 19% (4 of 21) of normal oral mucosa. While p27 expression was 60% in OSCCs. We found an inverse correlation between Jab1 and p27 expression levels (P<0.001). Kaplan-Meier survival analysis showed that Jab1 overexpression and p27 low expression were significantly associated with poor prognosis of patients. Our findings suggest that Jab1 expression is inversely correlated with p27 expression levels, suggesting that Jab1 overexpression contributes to pathogenesis of OSCC by degradating p27 expression. Furthermore, control of Jab1 could be a novel target of therapy in OSCCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22311264     DOI: 10.1007/s12032-012-0177-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  COP9 signalosome revisited: a novel mediator of protein degradation.

Authors:  C Schwechheimer; X W Deng
Journal:  Trends Cell Biol       Date:  2001-10       Impact factor: 20.808

2.  CSN5/Jab1 controls multiple events in the mammalian cell cycle.

Authors:  Akihiro Yoshida; Noriko Yoneda-Kato; Martina Panattoni; Ruggero Pardi; Jun-ya Kato
Journal:  FEBS Lett       Date:  2010-10-26       Impact factor: 4.124

3.  Estimates of the worldwide frequency of sixteen major cancers in 1980.

Authors:  D M Parkin; E Läärä; C S Muir
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

4.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1.

Authors:  K Tomoda; Y Kubota; J Kato
Journal:  Nature       Date:  1999-03-11       Impact factor: 49.962

5.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

6.  Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.

Authors:  Francisco J Esteva; Aysegul A Sahin; George Z Rassidakis; Linda X H Yuan; Terry L Smith; Ying Yang; Michael Z Gilcrease; Massimo Cristofanilli; Rita Nahta; Lajos Pusztai; François-Xavier Claret
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

7.  JAB1/CSN5: a new player in cell cycle control and cancer.

Authors:  Terry J Shackleford; Francois X Claret
Journal:  Cell Div       Date:  2010-10-18       Impact factor: 5.130

8.  Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma.

Authors:  You Wang; Yuchan Wang; Chun Cheng; Yuhong Ji; Yueming Zhao; Lin Zou; Aiguo Shen
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-13       Impact factor: 4.553

9.  Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas.

Authors:  Nozomi Hashimoto; Shinichi Yachida; Keiichi Okano; Hisao Wakabayashi; Katsumi Imaida; Kazutaka Kurokohchi; Tsutomu Masaki; Hisoka Kinoshita; Masahiro Tominaga; Tetsuo Ajiki; Yonson Ku; Takehiro Okabayashi; Kazuhiro Hanazaki; Makoto Hiroi; Sadanobu Izumi; Shohei Mano; Setsuo Okada; Yukihiko Karasawa; Takashi Maeba; Yasuyuki Suzuki
Journal:  Ann Surg Oncol       Date:  2008-11-26       Impact factor: 5.344

10.  Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma.

Authors:  Jihyun Ahn; Soon Auck Hong; Seung-Eun Lee; Jaetaek Kim; Yeon Sahng Oh; Sung Jun Park; Yun Jae Chung
Journal:  Endocr J       Date:  2009-05-20       Impact factor: 2.349

View more
  8 in total

Review 1.  Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer.

Authors:  Yunbao Pan; Huiling Yang; Francois X Claret
Journal:  Cancer Biol Ther       Date:  2014-02-04       Impact factor: 4.742

Review 2.  Jab1/Cops5: a promising target for cancer diagnosis and therapy.

Authors:  Chunjue Yuan; Dong Wang; Guohong Liu; Yunbao Pan
Journal:  Int J Clin Oncol       Date:  2021-05-21       Impact factor: 3.402

3.  p27Kip1 expression as a prognostic marker for squamous cell carcinoma of the head and neck.

Authors:  Miguel Reis DE Almeida; Mario Pérez-Sayáns; José Manuel Suárez-Peñaranda; José Manuel Somoza-Martín; Abel García-García
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

4.  Determination of Genes Related to Uveitis by Utilization of the Random Walk with Restart Algorithm on a Protein-Protein Interaction Network.

Authors:  Shiheng Lu; Yan Yan; Zhen Li; Lei Chen; Jing Yang; Yuhang Zhang; Shaopeng Wang; Lin Liu
Journal:  Int J Mol Sci       Date:  2017-05-13       Impact factor: 5.923

5.  Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia.

Authors:  Yunbao Pan; Dong Liu; Yongchang Wei; Dan Su; Chenyang Lu; Yanchao Hu; Fuling Zhou
Journal:  Front Pharmacol       Date:  2017-06-12       Impact factor: 5.810

Review 6.  Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer.

Authors:  Guohong Liu; Francois X Claret; Fuling Zhou; Yunbao Pan
Journal:  Front Pharmacol       Date:  2018-02-27       Impact factor: 5.810

Review 7.  The Role of Genetic Pathways in the Development of Chemoradiation Resistance in Nasopharyngeal Carcinoma (NPC) Patients.

Authors:  Norhafiza Mat Lazim; Che Ismail Che Lah; Wan Khairunnisa Wan Juhari; Sarina Sulong; Bin Alwi Zilfalil; Baharudin Abdullah
Journal:  Genes (Basel)       Date:  2021-11-21       Impact factor: 4.096

Review 8.  Targeting the COP9 signalosome for cancer therapy.

Authors:  Wenqi Du; Ruicheng Zhang; Bilal Muhammad; Dongsheng Pei
Journal:  Cancer Biol Med       Date:  2022-03-21       Impact factor: 5.347

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.